Sionna Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Sionna Therapeutics, Inc. on June 17, 2026. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol "SION".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date of April 21, 2026, there were 45,142,330 shares of common stock outstanding. The following proposals were approved:
- Election of Class II Directors: All four nominees were elected to serve until the 2029 Annual Meeting.
- Ratification of Auditors: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
| Proposal | Votes For | Votes Against/Withheld | Abstentions/Non-Votes |
|---|---|---|---|
| Election of Directors (Aggregate) | 164,232,739 | 4,601,621 | 4,337,320 |
| Ratify Auditors | 43,291,215 | 1,198 | 507 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting process.
Key Facts for Investor Verification
- Verify the full Definitive Proxy Statement filed on April 27, 2026, for detailed biographies of the newly elected directors and the rationale for the auditor appointment.
- Confirm the total number of shares outstanding (45,142,330) as of the April 21, 2026 record date.
- Note that the Company maintains its status as an emerging growth company.